- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma ...
It is decisive to dispel misinformation about this silent eye condition, which poses a threat to vision without displaying early warning signs Glaucoma comprises a set of eye disorder characterised by ...
Bayer to present new analyses from pivotal trials PULSAR & PHOTON featuring Eylea 8 mg at EURETINA: Berlin Thursday, September 12, 2024, 17:00 Hrs [IST] Bayer will present new ana ...